| CPC A61K 47/58 (2017.08) [A61K 47/60 (2017.08); A61K 47/65 (2017.08); C08F 220/286 (2020.02)] | 14 Claims |
|
1. A polymer-drug conjugate of formula I in the form of a block co-polymer for delivery of therapeutic agents
![]() wherein:
R1, R2 and R3 are independently selected from H or −CH3;
x is a natural number between 1-100;
y is a natural number between 1-100;
n is a natural number between 1-50;
L is a cleavable linker;
D is a therapeutic agent that is combretastatin or 5-Fluorouracil (5-FU) or gemcitabine or chloroquine or doxorubicine;
A is an end group or A may be null; and
B is an end group or B may be null,
wherein: (a) A is (i) an end group that is a fragment of a chain transfer agent (CTA), an initiator or a fragment of a CTA, or (ii) an initiator conjugated with a targeting moiety selected from the group consisting of antibodies, antibody fragments, and peptides, a fragment of a CTA or initiator having a reactive functional group selected from the group consisting of: acetal, hemiacetal, carboxylic acid, alcohol, amide, imide, anhydride, aryl halide, azo compound, diazo compound, hydrazine, azide, carbonate, chlorosilane, cyanide, ester, sulfate ester, phosphate ester, thiophosphate ester, isocyanate, isothiocyanate, thiocarbamate ester, and dithiocarbamate ester; (b) B is an end group that is a fragment of a chain transfer agent or initiator; and (c) the polymer-drug conjugate is made by a method comprising:
polymerizing PEG (meth)acrylate monomer (formula II)
![]() to provide a polymer of formula IIa:
![]() (ii) reacting formula IIa with a (meth)acrylate-L-D monomer (formula IIIa)
![]() to give polymer-drug conjugate of formula I.
|